Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sur

Showing results (141-150 of 146) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 146 results.
Molecular Psychiatry|January 28, 2015
Dysregulation of miR-34a links neuronal development to genetic risk factors for bipolar disorderS Bavamian, N Mellios, J Lalonde, et al.
Molecular Psychiatry|April 30, 2015
Noncoding RNAs connect genetic risk factors to the neurodevelopmental basis of bipolar disorderS Bavamian, N Mellios, J Lalonde, et al.
Molecular Psychiatry|April 26, 2017
MeCP2-regulated miRNAs control early human neurogenesis through differential effects on ERK and AKT signalingN Mellios, D A Feldman, S D Sheridan, et al.
Bioorganic & Medicinal Chemistry Letters|April 24, 2016
Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitorsThomas J Greshock, John M Sanders, Robert E Drolet, et al.
Bioorganic & Medicinal Chemistry Letters|April 23, 2010
3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead effortsEdward J Brnardic, Mark E Fraley, Robert M Garbaccio, et al.
Journal of Medicinal Chemistry|March 1, 2017
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D Scott, Duane E DeMong, Thomas J Greshock, et al.
Pageof 15

Showing results (141-150 of 146) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 146 results.
Molecular Psychiatry|January 28, 2015
Dysregulation of miR-34a links neuronal development to genetic risk factors for bipolar disorderS Bavamian, N Mellios, J Lalonde, et al.
Molecular Psychiatry|April 30, 2015
Noncoding RNAs connect genetic risk factors to the neurodevelopmental basis of bipolar disorderS Bavamian, N Mellios, J Lalonde, et al.
Molecular Psychiatry|April 26, 2017
MeCP2-regulated miRNAs control early human neurogenesis through differential effects on ERK and AKT signalingN Mellios, D A Feldman, S D Sheridan, et al.
Bioorganic & Medicinal Chemistry Letters|April 24, 2016
Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitorsThomas J Greshock, John M Sanders, Robert E Drolet, et al.
Bioorganic & Medicinal Chemistry Letters|April 23, 2010
3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead effortsEdward J Brnardic, Mark E Fraley, Robert M Garbaccio, et al.
Journal of Medicinal Chemistry|March 1, 2017
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D Scott, Duane E DeMong, Thomas J Greshock, et al.
Pageof 15